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Prostate cancer (PCa) is a slow-growing tumor representing one of the major causes of all
new cancer cases and cancer mortality in men worldwide. Although screening methods
for PCa have substantially improved, the outcome for patients with advanced PCa
remains poor. The elucidation of the molecular mechanism that drives the progression
from a slow-growing, organ-confined tumor to a highly invasive and castration-resistant
PCa (CRPC) is therefore important. We have already proved the diagnostic potential
of indoleamine-2,3-dioxygenase (IDO) when detected in urine of individuals at risk of
developing PCa. The aim of this study was to implement IDO as a prognostic marker for
PCa patients undergoing surgical treatment. We have thus conducted an observational
study by collecting 100 urine samples from patients undergoing radical prostatectomy
as first treatment of choice. To test the integrity of our investigation, scale dilution cells
of an established PC3 cell line were added to urine of healthy donors and used for gene
expression analysis by a TaqMan assay on the catalytic part of IDO mRNA. Our data
show that the quantification of IDO mRNA in urine of patients has a very promising ability
to identify patients at high risk of cancer advancement, as defined by Gleason score.
Our goal is to lay the groundwork to develop a superior test for PCa. The data generated
are thus necessary (i) to strengthen the IDO-based diagnostic/prognostic test and (ii) to
provide patients and clinicians with an affordable and easy screening test.
Keywords: prostate cancer, IDO—indoleamine 2,3-dioxygenase, prognostic marker, liquid biopsy, radical
prostatectomy, immune regulation, inflammation
INTRODUCTION
Prostate cancer (PCa) represents the first leading cause of cancer morbidity and the third of
cancer death in men in developed countries, with a worldwide incidence rate accounting for
14% of total newly diagnosed cases and a worldwide total cancer mortality rate of 6% (1). It
is of relevance that prostate tissues appear to be characterized by features consistent with an
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immunosuppressive microenvironment. Infiltrating CD4+ and
CD8+ T lymphocytes (TILs) are predominantly characterized by
regulatory (2, 3) and functionally exhausted (PD-1+, B7-H1+)
phenotypes (4–6). Furthermore, enhanced suppressive function
of adaptive CD4+ Treg has been observed in the peripheral
blood of patients with PCa and found to correlate with metastatic
behavior (7).
The tumor microenvironment is the battlefield where not
well-defined relationships between oncogenesis and immune
surveillance to cancer take place. Tumor immune escape occurs
through the secretion of different tumor-derived factors (TDFs)
with immunosuppressive properties, such as indoleamine-2,3-
dioxygenase (IDO). The specific IDO gene product plays a
key role in tryptophan metabolism, and its enhanced activities
might result in both the depletion of an amino acid essential
for lymphocyte metabolism and in the generation of toxic
metabolites (8).
The significant correlation between levels of expression of
IDO and its activity (kynurenine/tryptophan ratio) in PCa
specimens, the trend seen in relation to PCa patients’ clinical
features [Gleason score (GS)], and the finding that TGF-β
expression was significantly correlated to IDO gene expression
in PCa contributed to the identification of a peculiar subset of
tumors (9). A high level of IDO has been reported to be correlated
with poor clinical prognosis in cancers, such as ovarian cancer
(10), endometrial cancer (11), colon carcinomas (12), malignant
melanoma (13), and lung cancer (14). In renal cell carcinoma,
levels of IDO mRNA in primary tumors or metastasis do not
correlate with longer overall survival. In this specific setting,
IDO was nearly exclusively expressed in endothelial cells of
predominantly newly formed blood vessels, not in tumor cells,
a condition that presumably inhibits tumor growth due to amino
acid tryptophan depletion to cancer cells (15).
Currently, the selection of patients at risk of PCa and
the indication for biopsy are based on the combination of
prostate-specific antigen (PSA) blood test and the digital rectal
examination (DRE) of the organ (16). Although PSA is the
most commonly used screening parameter, it has a relatively
poor specificity for PCa, which means that patients with benign
prostate hyperplasia (BPH) or prostatitis might show higher
PSA values and might therefore undergo unnecessary biopsies
(17, 18).
To secure the diagnosis of PCa and to determine further
therapeutic interventions, a fine-needle biopsy is necessary,
although prostate sampling might be inconsistent at early
stages (19, 20). In addition, complications like hematuria,
hematospermia, and infection can occur during the procedure
(21). Therefore, unnecessary costs and complications should be
avoided for patients bearing no cancer lesions or an indolent
form. A reliable biomarker that could identify without the use
of biopsy patients with early aggressive or clinically significant
tumors and rule them out while being easy to collect in a non-
invasive procedure would be ideal (21, 22).
We have identified that the enzyme IDO could serve as a
novel diagnostic biomarker for PCa in urine. We have developed
a novel diagnostic approach based on the IDO mRNA and/or
protein levels. Our current data show that the quantification of
IDO mRNA in urine of patients has a very promising ability
to identify patients harboring PCa (23). Because patients with
higher expression of IDO in PCa at first diagnosis showed a
significantly higher risk of tumor recurrence after prostatectomy,
IDO may furthermore be used also as a recurrence marker.
Therefore, in this study, we evaluated the prognostic value
of IDO gene expression in urine of PCa patients undergoing
radical prostatectomy (RP) as first-line treatment. Urine was
collected preoperatively, and results were correlated with
clinicopathological characteristics.
MATERIALS AND METHODS
Patients’ Accrual and Clinicopathological
Characteristics
We evaluated a case series of 100 patients bearing PCa
at first diagnosis and undergoing RP as first treatment of
choice in our institution between June 2016 and June 2017.
Relevant clinical data were collected by reviewing patients’ files.
Clinicopathological parameters (PSA levels, tumor stage, and GS
were assigned according to European Association of Urology
(EAU) guidelines for PCa; uroweb.org/guidelines/prostate-
cancer/). Local ethics committee approval and written
informed consent from patients were obtained in accordance
with the requirements of the Ethical Committee of Zürich
(BASEC_2018-02101).
Urine Processing
Urine of 20 to 50ml was voided in DNA/RNA preservative cups
(Sierra Diagnostic, USA) before RP. Depending on amount of
urine collected, two-way processing was carried out: (i) for 20–
50 cm3 of urine, the extraction of RNA was performed by using
urine pellet generated after urine centrifugation at 2,000 rpm
for 10min at 4◦C. (ii) For limited amount of urine (<20 cm3),
the quantification of cell-free RNA was considered, and urine
samples were aliquoted at 500 µl each test. Either pellet or cell-
free RNA urine was treated with 700µl of lysis solution (Ambion,
USA), stored at −80◦C or immediately used for RNA extraction
(Ambion, USA). Total urine was used to test IDO enzymatic
activity through the L-kynurenine/tryptophan ratio, as analyzed
by ELISA (Immundiagnostik).
Established Prostate Cancer Cell Line
Spiked in Patients’ Urine
PC3 is an established cells line from bone metastasis and
produces a high level of IDO constitutively (23). PC3 was
cultured in Roswell Park Memorial Institute (RPMI) 1640
medium containing 2mM of L-glutamine (Invitrogen, Carlsbad,
CA) together with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA), 100 U/ml of penicillin, and 100µg/ml of
streptomycin. Urine from healthy donors spiked with PC3 was
used as control or to validate our system. Accordingly, IDO gene
expression was tested by plating PC3 cell line in four different
sized growing areas (150, 75, 25, and 6 cm2) and cultured for
72 h, as previously described by us in Poyet et al. (24). Cells were
harvested at about 90% confluence. Scale dilution of cells was
added to urine of HD, and pellet was used for gene expression.
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FIGURE 1 | (A) Correlation between scale dilution of established PC3 cells line and total RNA extraction. Red dots represent number of seeded cells per growing area
(6, 25, 75, and 150 cm2, respectively); blue dots represent amount of extracted total RNA from harvested cells per growing area (6, 25, 75, and 150 cm2,
respectively). The test shows that correlation between number of harvested cells <1 × 106 and total RNA (B) or RNA in ng/µl (C) was markedly confirmed. Error bars
represent the mean ± SD of three replicates.
Gene Expression Analysis
Total RNA extraction was performed by using the RNAqueous
Kit according to the manufacturer’s protocol (Applied
Biosystems, USA). After extraction, RNA undertook DNase
treatment and was subsequently retrotranscribed into cDNA
(High Capacity cDNA Reverse Transcription Kit, Applied
Biosystems). Quantitative gene amplification (qRT-PCR) was
set up according to standard real-time PCR protocols using a
Corbett Life Science Rotor-gene 3000 instrument (Corbett Life
Science, Sydney, Australia) using TaqMan R© Universal PCR
Master Mix Reagents Kit (Labgene) and “on demand” sets of
primers and probes for housekeeping genes (RNA ribosomal
18S and β-actin) (Thermo Fisher, Switzerland). The IDO
assay (Custom TaqMan primers and probe design; Applied
Biosystems) was designed to cover the exon–exon junction
between exons 9 and 10. Primers were designed to allow a
melting temperature of between 58 and 61◦C, with an optimal
length of 20 bp and CG content between 30 and 80%. The
probe was designed not to start with G and in order to have a
melting temperature 10◦C higher than the one of the primers. A
3
′
minor grove binder-probe [non-fluorescent quencher fitting
the 5(6)-carboxyfluorescein (FAM) spectral qualities] was used.
Primers and probe were used at a final concentration of 400
and 200 nM, respectively. TaqMan assay sequences are described
in patent “INDOLEAMINE-2,3-DIOXYGENASE ASSAY FOR




One microliter of cDNA was loaded into the TaqMan reaction
mix, and reactions were run in a final volume of 20 µl. The
reaction conditions were set accordingly to the manufacturer’s
instructions (TaqMan Gene Expression Master Mix, Applied
Biosystems, USA). The absolute quantification of each gene’s
copies was calculated through the generation of a standard
curve by serial dilution of synthetic oligonucleotides. Data were
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FIGURE 2 | IDO gene expression (in CT, threshold cycle) from non spiked PC3 urine of healthy donors (A), as compared with its expression from PC3-spiked
counterpart (B). Gene expression of TGF-β, a tumor-derived soluble factor involved in PCa progression, in either non spiked PC3 (C) or PC3-spiked (D) urine, has
been used as control. Error bars represent the mean ± SD of three replicates. IDO, indoleamine-2,3-dioxygenase.
then given in copies per milliliter of urine. Where appropriate,
RNA ribosomal 18S and β-actin were used as endogenous
reference genes, and normalized data were be analyzed by the
2−11Ct method.
Measurement of Tryptophan, Kynurenine,
and Quinolinic Acid Concentration
IDO activity was measured in urine and performed as L-
kynurenine vs. L-tryptophan (Kyn/Trp ratio) or quinolinic acid
A vs. L-tryptophan (Q-A/Trp ratio) concentrations by ELISA
according to manufacturer’s instructions (Immundiagnostik,
Bensheim, Germany). In addition, IDO protein release in urine
of patients was analyzed as well by ELISA (Immundiagnostik,
Bensheim, Germany).
Statistical Analysis
Statistical analysis was performed with GraphPad Prism (v5.1)
and SPSS (v23). Non-parametric tests for gene expression
levels (Mann–Whitney U-test and Kruskal–Wallis test) were
run. Categorical variables were evaluated by contingency table
analyses and Pearson chi-square test or Fisher exact test, as
appropriate. Two-sided p < 0.05 (95% CI) were considered
statistically significant. The performance of IDO as prognostic
factor in PCa was evaluated by calculating the area under the
receiver operating characteristic (ROC) curve (AUC). Previous
cutoffs were confirmed by sensitivity, specificity, positive




Expression in Urine Represents a Valuable
Test for Prostate Cancer Prognosis by
Liquid Biopsy
To test the integrity of our investigation, which is the positive
correlation between IDO gene expression in urine and number
of cancer cells, PC3 cells were spiked in urine of healthy donors
at various concentrations, as described in the Materials and
Methods. To standardize IDO gene expression, the number of
harvested cells was correlated with the amount of total RNA
extracted after cell harvesting.
We first observed a positive correlation between number
of cells harvested and total RNA extracted (Figure 1A). We
additionally observed that the correlation between number of
cells <1 × 106 and RNA concentration, either total (Figure 1B)
or in ng/µl (Figure 1C) was markedly confirmed (R2 < 0.9). To
mimic prostate massage yield, the same numbers of cells were
spiked into urine. We observed that IDO gene expression was
confirmed as equal as IDO gene expression from non-spiked
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FIGURE 3 | Fold change in IDO and PSA gene expression in five PCa patients
before/after DRE. Amount of IDO mRNA is significantly maintained in urine of
PCa patients undergoing DRE (∼2-fold-increase), as compared with its
expression in urine of same PCa patients before DRE. Differently, PSA value
abundantly increased over 2-fold. Error bars represent the mean ± SD of three
replicates. IDO, indoleamine-2,3-dioxygenase; PSA, prostate-specific antigen;
PCa, prostate cancer; DRE, digital rectal examination.
cells (Figures 2A,B), although 1Ct between spiked and non-
spiked urine was of about 2logs (p > 0.5). In addition, IDO gene
expression showed a linear regression value higher than TGF-β
gene expression, a cytokine constitutively expressed in PC3 cell
lines (Figures 2C,D). Despite spiked urine showing higher IDO
gene expression, the latter is not markedly strong to justify the
use of prostate massage for IDO testing.
Detection of Indoleamine-2,3-Dioxygenase
Gene in Urine Does Not Need Prostate
Massage and Can Be Performed Either by
Urine Pellet or by Cell-Free RNA
One of the major limitations in performing gene expression in
urine is the amount of RNA. For PCa diagnosis, this hurdle can
be overcome by squeezing the organ through a prostate massage
and extracting RNA from urine pellet. However, prostatemassage
is not always feasible. We analyzed IDO gene expression in urine
of five patients undergoing PCa standard diagnosis (PSA level +
DRE) collected before and after DRE. PSA gene expression was
used as control. We observed that change in IDO gene expression
was abundantly lower (∼2-fold) than that of PSA (30-fold; p <
0.001; Figure 3). In addition, no significant differences for IDO
gene expression were observed between pellet and cell-free RNA
of urine collected before DRE (data not shown).
The Prognostic Potential of
Indoleamine-2,3-Dioxygenase for
Diagnosed Prostate Cancer Can Redirect
Treatment Options
Out of 100 patients enrolled in this study, 20 were excluded
owing to lack of complete clinicopathological parameters (TNM
and GS after RP) and limited amount of material for IDO gene
expression (rRNA 18S almost negligible; Ct> 30). By distributing
patients on the basis of GS (GS ≤ 7; n = 60 and GS ≥ 8; n =
20), we found a significant variation for IDO gene expression in
urine (GS ≤ 7 = mean 0.029 ± 0.046; median 0.012; GS ≥ 8
= 0.031 ± 0.075; median 0.033; p < 0.01; Figure 4A). To better
determine the association between IDO gene expression in urine
and cancer aggressiveness, we distributed patients on the basis of
all GS patterns from GS= 7 to GS= 10 (no GS= 6 was reported,
because indolent patients preferably undergo active surveillance).
Therefore, we grouped our patients as follows: GS = 7 (3 + 4), n
= 32; GS = 7 (4 + 3), n = 28; GS = 8, n = 12; and GS = 9 (4 +
5), n = 8. No PCa with GS = 9 (5 + 4) or GS = 10 was reported
in our group of patients. A Kruskal–Wallis test was initially run
to test mean variations among groups (p < 0.01). We found a
significant difference of IDO gene expression in urine between
patients with GS= 7 (3+ 4) and GS= 7 (4+ 3) (p= 0.03), GS=
8 (p< 0.01), andGS= 9 (4+ 5) (p< 0.01), whereas no significant
differences were observed between GS = 7 (4 + 3) and higher
scores [GS = 8 and GS = 9 (4 + 5)] (Figure 4B). Notably, no
significant differences were observed for TNM distribution (data
not shown).
To confirm the cutoff value previously defined (23), we run
two ROC curves tests comparing PCa with GS = 7 (3 + 4) vs.
GS= 7 (4+ 3)/higher score and GS ≤ 7 vs. GS ≥ 8. The AUC to
dichotomize patients with indolent or aggressive PCa on the basis
of on GSs either partially confirmed or ameliorated the sensitivity
and specificity of the test calculated with the cutoff level defined
previously (0.0096). Indeed, for GS = 7 (3 + 4) vs. GS = 7 (4
+ 3)/higher score, the best cutoff level was 0.0123 (sensitivity
61% and specificity 60%), whereas at the cutoff level of 0.0096,
the sensitivity was 70% and the specificity 53% (Figure 4C).
Differently, for GS ≤ 7 vs. GS ≥ 8, the best cutoff level was
0.0288 (sensitivity 71% and specificity 78%), whereas at cutoff
level of 0.0096, the sensitivity was 61% and the specificity was 60%
(Figure 4D).
Indoleamine-2,3-Dioxygenase Enzymatic
Activity Might Predict Prostate Cancer
Clinical Outcome
To confirm previous finding, the IDO activity (Kyn/Trp ratio
or Q-A/Trp ratio) and IDO protein release were analyzed
in 15 selected PCa patients with different GS (7 to 9). In
keeping with IDO mRNA expression in urine, IDO activity
characterized by Q-A/Trp ratio correlated with GS (7–9) (R2
0.88, p < 0.001; Figure 5A), whereas activity by Kyn/Trp
ratio did not (data not shown). In addition, IDO protein
release (ng/ml) showed a tendency with GS (7–9) (p = 0.07),
although the correlation was inversed and not significant
(R2 0.24, p= 0.3; Figure 5B).
DISCUSSION
PCa is the most frequently diagnosed cancer among men in first-
world countries and one of the leading causes of cancer-related
death in men (22).
The management of PCa is still difficult, as indolent
tumors often do not have any effect on the patient’s life
expectancy and therefore need a minimum or no treatment.
In contrast, aggressive forms can grow and metastasize
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FIGURE 4 | IDO gene expression correlated with Gleason score either (A) when comparing GS ≤ 7 vs. GS ≥ 8 or (B) when expressing single GS patterns. A ROC
(AUC 0.7) (C) that compared Gleason score 7 (3 + 4) vs. 7 (4 + 3)/higher failed to confirm a previously defined cutoff for discriminating indolent vs. aggressive PCa,
while a ROC (AUC 0.8) (D) that compared GS ≤ 7 vs. GS ≥ 8 did confirm a previous cutoff for discriminating indolent vs. aggressive PCa. IDO,
indoleamine-2,3-dioxygenase; GS, Gleason score; ROC, receiver operating characteristic; AUC, area under the ROC curve; PCa, prostate cancer.
quickly, which often leads to life-impairing consequences (25).
For clinical stratification, the PSA, tumor size, and GS are
being used.
Recently, urine-based biopsy has been considered the gold
standard owing to the non-invasive procedure for their
collection. Indeed, there are many new approaches that use urine
as liquid biopsy for PCa diagnosis/prognosis, such as circulating
tumor cells (26) and cell-free DNA (27) tests.
Recent studies showed the potential of IDO as such a novel
marker (9, 23). The enzyme IDO is expressed in many tumor
types including PCa and seems to contribute to the tumor’s
immunosuppressive abilities by converting tryptophan into
kynurenine (28–30). It was shown that immunohistochemically
measured IDO gene expression in prostate biopsies is highly
specific for PCa (9). However, a clinically more viable way of
measuring is required. A urine-based analysis of IDO RNA
expression of men at risk of PCa development showed that it
could reduce the number of unnecessary biopsies by 14.8–66.6%
depending on the cutoff level (23).
Clinicians need a reliable, easy-to-handle, and affordable
screening test. The IDO mRNA-based assay is possible in
clinical/practitioner’s routine. In our opinion, this IDO gene
expression analysis in urine of PCa patients is stronger than
a protein test in terms of sensitivity and affordability. Further
investigation on larger cohort of patients is needed to confirm
the results achieved at both studies with enough statistical power;
to finalize the final procedures for a better detection of IDO; to
rate with accurate estimation the sensitivity of this test; and to
evaluate in more detail the significance of IDO localization in
biopsies as a marker for the risk of biochemical recurrence.
The PSA blood test, despite being the gold standard for PCa
active surveillance and recurrence, has several limitations for
screening patients at risk of PCa. This is due to the following:
(i) PSA is organ specific but not tumor specific. Elevated levels
of PSA can be found in other pathologies (benign prostatic
hyperplasia, and acute prostatitis) or in physiological conditions,
such as age increase and sexual activity; (ii) PSA test lacks
sensitivity because only 25% of patients with PSA of between 2.5
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FIGURE 5 | IDO activity characterized by Q-A/Trp ratio in 15 selected PCa with different GS (7–9) correlated with GS (R2 0.88, p < 0.001 (A). Differently, IDO protein
release (ng/ml) inversely correlated with GS (B). IDO, indoleamine-2,3-dioxygenase; PCa, prostate cancer; GS, Gleason score.
and 10 ng/ml, gray zone, show positive biopsies; and (iii) PSA is
not indicative of tumor staging and grading alone.
Improving current methods for screening of patients is
therefore of great importance and will positively affect a
significant part of the population. We have identified IDO
as an important player in the mechanisms that regulate
PCa progression and clarified its role and activity in these
settings. Tumor cells expressing IDO have a higher chance of
escaping the immune surveillance, and due to the presence
of IFNγ and TNFα in the tumor microenvironment, they
have a greater ability to migrate and invade. Furthermore,
patients with higher expression of IDO in PCa at first
diagnosis showed a significantly higher risk of tumor recurrence
after prostatectomy.
Particularly in PCa, the expression of tumor-derived soluble
factors (TDSFs) able to impair the functions of immune system
in patients has been defined by us in Banzola et al. (23). In this
context, we previously observed that cytokine possibly involved
in PCa progression (such as IL-6) was found significantly higher
expressed in PCa specimens, as compared with BPH (9). This
information was confirmed by cytokine detection in sera of PCa
patients (31).
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In addition, arginase production by macrophages infiltrating
prostatic tissues has been shown to favor the induction of anergy
in resident lymphocytes (4). In this context, cytokines might play
a relevant role in coordinating cancer immunoediting (32).
In conclusion, we proved that the quantification of IDO
mRNA in the urine of PCa patients is a potential prognostic tool
for this malignancy. This dataset is large enough to support the
use of IDO as a recurrent marker in PCa patients undergoing RP
as the first treatment of choice. However, in order to strengthen
IDO as a robust prognostic marker for the identification of
patients at higher risk of PCa recurrence, additional data on
clinical samples from a larger cohort and the improvement of
data acquisition for a more reliable IDO enzymatic activity are
needed. Thus, the IDO detection in the urine of PCa patients
could contribute, together with the standard parameters for the
diagnosis/prognosis of this disease, to improve its outcome.
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